THIS WEBSITE USES COOKIES
We use cookies to personalise content, to provide social media features, and to analyse our traffic. By choosing 'allow all cookies', you consent to our cookies.
To find out more, read our privacy policy and cookie policy.

GLIOMATCH selected for Horizon Europe funding

The GLIOMATCH project aimed at advancing precision medicine for brain cancer patients has received a total funding of €12.59 million from the EU, Switzerland, and the UK.

GLIOMATCH is now a Horizon Europe funded Research and Innovation Action. The project is aimed at improving the outcome of malignant brain tumours in adults and children, as well as better understanding immunotherapy for brain cancer treatment.

By investigating solutions to alleviate the societal impacts of brain cancer, the project aligns with the objectives of the EU Cancer Mission and contributes to the United Nations’ Sustainable Development Goals 2 and 4.

It is a five year project starting in January 2024 and aligning 14 pan-European partners from 10 different member states.

More Posts

GLIOMATCH 3rd consortium meeting takes place in Düsseldorf, Germany

From 25 to 27 March 2025, the GLIOMATCH consortium convened in Düsseldorf, Germany, for its third consortium meeting. The meeting was held in-person and hosted by the partner University of Düsseldorf (UDUS). Over 40 experts from across Europe gathered to assess progress of the past year and plan the next phase of the GLIOMATCH project.

World Cancer Day 2025

On World Cancer Day 2025, the GLIOMATCH project participated in the EU project showcase hosted by HaDEA, highlighting the role of EU-funded research in advancing cancer care. We have seized this opportunity to map the EU Cancer Mission project landscape.